Urinary 8-hydroxy-2'-deoxyguanosine, a metabolite of oxidized DNA, is not elevated in HIV patients on combination antiretroviral therapy.
Mitochondrial toxicity of nucleoside analogues has been proposed to be the etiology of a range of side-effects from antiretroviral therapy of HIV infection. In this study, urinary 8-hydroxy-2'-deoxyguanosine (8OH2'dG), a metabolite of oxidized DNA, was measured to determine if antiretroviral therapy leads to oxidative damage to DNA. A cross-sectional study was carried out measuring urinary 8OH2'dG in three groups of HIV-infected patients: (1) antiretroviral medication naïve, (2) patients on antiretroviral medications without lipodystrophy and (3) patients on antiretroviral medications with lipodystrophy. Twenty-five patients were enrolled in each group. The mean spot urinary 8OH2'dG measurements per mg creatinine for the three groups were: antiretroviral naïve 4.27 +/- 0.61 (ng 8OH2'dG/mg creatinine +/- SEM), on antiretroviral medications without lipodystrophy 2.88 +/- 0.26, and on antiretroviral medications with lipodystrophy 3.27 +/- 0.30. The differences between the means of the three groups is not statistically significant (p = 0.055), and these results are not significantly different from reported values for healthy controls [A carbon column-based liquid chromatography electrochemical approach to routine 8-hydroxy-2-deoxyguanosine measurements in urine and other biologic matrices: a one-year evaluation of methods. Free Radical Biology and Medicine 27 (1999) 647-666].
Paul
Simon
S
Department of Medicine, Division of Infectious Diseases, New York Presbyterian Hospital-Weill College of Medicine of Cornell University, New York, NY 10021, USA. sip2002@med.cornell.edu
Bogdanov
Mikhail B
MB
Matson
Wayne R
WR
Metakis
Linda
L
Jacobs
Jonathan
J
Beal
M Flint
MF
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D001824:Body Constitution; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D004249:DNA Damage; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000652:urine*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000473:pathology / Q000652:urine*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000473:pathology / Q000652:urine; D006801:Humans; D008297:Male; D018384:Oxidative Stress
D017320:HIV Protease Inhibitors; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine